Scientific Study Reveals:
Vyvanse® eases symptoms of Adult ADD/ADHD in as little as one week
In one of the largest controlled stimulant trials of adults with ADD/ADHD, Vyvanse® proved to be significantly more effective than a placebo at managing the symptoms of the disorder. And it did so for some in as short a time as one week.
Those are the results of the Phase II trial of Vyvanse, which the U.S. Food and Drug Administration approved last April for adult use. The drug had already been approved for use in children ages six to 12 years old in July 2007.
Vyvanse® passed not one, but two, standard medical markers of effectiveness. Using a randomized, double-blind, placebo-controlled, parallel-group study which lasted four weeks, the trial involved 414 adults between the ages of 18 to 55. The test also used all the possible dosage levels of Vyvanse ®– 30, 50 and 70 mg.
At each one of these levels the prescription medication, manufactured by Shire Corp. outperformed the placebo.
Researchers used the ADHD Rating Scale which contains 18 separate diagnostic criteria as outlined by the Diagnostic and Statistical Manual of Mental Disorders, the official publication of the American Psychiatric Association. This scale is a validated method for assessing ADD/ADHD symptoms. Using this scale symptoms were reduced by up to 45 percent.
The scientists also used another measurement marker, the Clinical Global Impressions-Improvement scale as well. The percentage of adults who experienced a reduction of symptoms using Vyvanse who said they were “much improved” or “very much improved” according to investigators, ranged from 57 to 61 percent by the end of the study.
If you would like to view the entire article regarding this trial, you can click here.
[tags] vyvanse, ADHD Medication, Adult ADHD, Adult ADD [/tags]